Literature DB >> 23166318

Differential regulation of extracellular tissue inhibitor of metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein receptor-related protein 1.

Simone D Scilabra1, Linda Troeberg, Kazuhiro Yamamoto, Hervé Emonard, Ida Thøgersen, Jan J Enghild, Dudley K Strickland, Hideaki Nagase.   

Abstract

Tissue inhibitor of metalloproteinases-3 (TIMP-3) plays a key role in regulating extracellular matrix turnover by inhibiting matrix metalloproteinases (MMPs), adamalysins (ADAMs), and adamalysins with thrombospondin motifs (ADAMTSs). We demonstrate that levels of this physiologically important inhibitor can be regulated post-translationally by endocytosis. TIMP-3 was endocytosed and degraded by a number of cell types including chondrocytes, fibroblasts, and monocytes, and we found that the endocytic receptor low density lipoprotein receptor-related protein-1 (LRP-1) plays a major role in TIMP-3 internalization. However, the cellular uptake of TIMP-3 significantly slowed down after 10 h due to shedding of LRP-1 from the cell surface and formation of soluble LRP-1 (sLRP-1)-TIMP-3 complexes. Addition of TIMP-3 to HTB94 human chondrosarcoma cells increased the release of sLRP-1 fragments of 500, 215, 160, and 110 kDa into the medium in a concentration-dependent manner, and all of these fragments were able to bind to TIMP-3. TIMP-3 bound to sLRP-1, which was resistant to endocytosis, retained its inhibitory activity against metalloproteinases. Extracellular levels of sLRP-1 can thus increase the half-life of TIMP-3 in the extracellular space, controlling the bioavailability of TIMP-3 to inhibit metalloproteinases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23166318      PMCID: PMC3537031          DOI: 10.1074/jbc.M112.393322

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix.

Authors:  W H Yu; S Yu; Q Meng; K Brew; J F Woessner
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

2.  Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors.

Authors:  Carl Fisher; Natalia Beglova; Stephen C Blacklow
Journal:  Mol Cell       Date:  2006-04-21       Impact factor: 17.970

3.  Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma.

Authors:  K A Quinn; P G Grimsley; Y P Dai; M Tapner; C N Chesterman; D A Owensby
Journal:  J Biol Chem       Date:  1997-09-19       Impact factor: 5.157

Review 4.  Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability.

Authors:  A P Lillis; I Mikhailenko; D K Strickland
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

5.  Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site.

Authors:  M S Nielsen; A Nykjaer; I Warshawsky; A L Schwartz; J Gliemann
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

6.  Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.

Authors:  I R Horn; B M van den Berg; S K Moestrup; H Pannekoek; A J van Zonneveld
Journal:  Thromb Haemost       Date:  1998-11       Impact factor: 5.249

7.  Metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 ectodomain decreases endocytic clearance of endometrial matrix metalloproteinase-2 and -9 at menstruation.

Authors:  Charlotte Selvais; Héloïse P Gaide Chevronnay; Pascale Lemoine; Stéphane Dedieu; Patrick Henriet; Pierre J Courtoy; Etienne Marbaix; Hervé Emonard
Journal:  Endocrinology       Date:  2009-04-30       Impact factor: 4.736

8.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.

Authors:  A Nykjaer; C M Petersen; B Møller; P H Jensen; S K Moestrup; T L Holtet; M Etzerodt; H C Thøgersen; M Munch; P A Andreasen
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

9.  TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1.

Authors:  Marina Cardellini; Rossella Menghini; Eugenio Martelli; Viviana Casagrande; Arianna Marino; Stefano Rizza; Ottavia Porzio; Alessandro Mauriello; Anna Solini; Arnaldo Ippoliti; Renato Lauro; Franco Folli; Massimo Federici
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

10.  Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A. Evidence that this protein is required for uptake and degradation of multiple ligands.

Authors:  T E Willnow; J Herz
Journal:  J Cell Sci       Date:  1994-03       Impact factor: 5.235

View more
  37 in total

Review 1.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 2.  Metalloproteinases: a Functional Pathway for Myeloid Cells.

Authors:  Jonathan Chou; Matilda F Chan; Zena Werb
Journal:  Microbiol Spectr       Date:  2016-04

3.  Shedding of membrane-associated LDL receptor-related protein-1 from microglia amplifies and sustains neuroinflammation.

Authors:  Coralie Brifault; Andrew S Gilder; Emilia Laudati; Michael Banki; Steven L Gonias
Journal:  J Biol Chem       Date:  2017-09-28       Impact factor: 5.157

4.  Recombinant Expression of the Full-length Ectodomain of LDL Receptor-related Protein 1 (LRP1) Unravels pH-dependent Conformational Changes and the Stoichiometry of Binding with Receptor-associated Protein (RAP).

Authors:  Camilla De Nardis; Philip Lössl; Maartje van den Biggelaar; Pramod K Madoori; Nadia Leloup; Koen Mertens; Albert J R Heck; Piet Gros
Journal:  J Biol Chem       Date:  2016-12-12       Impact factor: 5.157

Review 5.  Tissue inhibitor of matrix metalloproteinase-3 has both anti-metastatic and anti-tumourigenic properties.

Authors:  Geetanjali P Rai; Sarah K Baird
Journal:  Clin Exp Metastasis       Date:  2020-01-01       Impact factor: 5.150

Review 6.  Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature.

Authors:  Dianaly T Au; Allison L Arai; William E Fondrie; Selen C Muratoglu; Dudley K Strickland
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

Review 7.  Serpins in cartilage and osteoarthritis: what do we know?

Authors:  David J Wilkinson
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

8.  High-Affinity Binding of LDL Receptor-Related Protein 1 to Matrix Metalloprotease 1 Requires Protease:Inhibitor Complex Formation.

Authors:  Allison L Arai; Mary Migliorini; Dianaly T Au; Elizabeth Hahn-Dantona; David Peeney; William G Stetler-Stevenson; Selen C Muratoglu; Dudley K Strickland
Journal:  Biochemistry       Date:  2020-08-06       Impact factor: 3.162

9.  Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding.

Authors:  Kazuhiro Yamamoto; Kathryn Owen; Andrew E Parker; Simone D Scilabra; Jayesh Dudhia; Dudley K Strickland; Linda Troeberg; Hideaki Nagase
Journal:  J Biol Chem       Date:  2014-01-28       Impact factor: 5.157

10.  Assessment of prognostic value of tissue inhibitors of metalloproteinase 3 (TIMP3) protein in ovarian cancer.

Authors:  Sahar Hakamy; Mourad Assidi; Mohammad A Jafri; Taoufik Nedjadi; Heba Alkhatabi; Abrar Al-Qahtani; Jaudah Al-Maghrabi; Khalid Sait; Mohammed Al-Qahtani; Abdelbaset Buhmeida; Adeel Chaudhary
Journal:  Libyan J Med       Date:  2021-12       Impact factor: 1.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.